Onyee Chan

1.8k total citations
115 papers, 942 citations indexed

About

Onyee Chan is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Onyee Chan has authored 115 papers receiving a total of 942 indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Hematology, 55 papers in Genetics and 19 papers in Molecular Biology. Recurrent topics in Onyee Chan's work include Acute Myeloid Leukemia Research (78 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (34 papers) and Chronic Myeloid Leukemia Treatments (29 papers). Onyee Chan is often cited by papers focused on Acute Myeloid Leukemia Research (78 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (34 papers) and Chronic Myeloid Leukemia Treatments (29 papers). Onyee Chan collaborates with scholars based in United States, China and France. Onyee Chan's co-authors include Eric Padron, Kendra Sweet, Jeffrey E. Lancet, Rami S. Komrokji, David A. Sallman, Ṭal Ilan, Matthew R. Palmer, Ke Wang, C. Ronald Kahn and Jeffrey English and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Clinical Oncology.

In The Last Decade

Onyee Chan

96 papers receiving 930 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Onyee Chan United States 13 397 263 244 193 149 115 942
Gualtiero Mariani Italy 14 267 0.7× 77 0.3× 497 2.0× 105 0.5× 47 0.3× 18 927
Jon Smythe United Kingdom 15 65 0.2× 42 0.2× 329 1.3× 120 0.6× 42 0.3× 25 752
Elena Ossipova Sweden 13 76 0.2× 67 0.3× 331 1.4× 56 0.3× 83 0.6× 30 1.1k
Susan K. Brusnahan United States 12 89 0.2× 50 0.2× 102 0.4× 61 0.3× 51 0.3× 18 449
Arnon Nagler Israel 13 167 0.4× 206 0.8× 105 0.4× 33 0.2× 81 0.5× 25 613
Sharon H. Choi United States 8 523 1.3× 22 0.1× 206 0.8× 649 3.4× 20 0.1× 15 1.1k
Natalie Wolkow United States 16 218 0.5× 46 0.2× 316 1.3× 134 0.7× 62 0.4× 76 881
J Živný Czechia 14 129 0.3× 64 0.2× 333 1.4× 94 0.5× 38 0.3× 40 671
Shohei Yokota Japan 14 966 2.4× 63 0.2× 467 1.9× 408 2.1× 32 0.2× 57 1.5k
Hong‐Wei Gao Taiwan 18 44 0.1× 23 0.1× 298 1.2× 55 0.3× 81 0.5× 85 963

Countries citing papers authored by Onyee Chan

Since Specialization
Citations

This map shows the geographic impact of Onyee Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Onyee Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Onyee Chan more than expected).

Fields of papers citing papers by Onyee Chan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Onyee Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Onyee Chan. The network helps show where Onyee Chan may publish in the future.

Co-authorship network of co-authors of Onyee Chan

This figure shows the co-authorship network connecting the top 25 collaborators of Onyee Chan. A scholar is included among the top collaborators of Onyee Chan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Onyee Chan. Onyee Chan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jiang, Jihong, Vijay Suresh Akhade, Joshua Bridgers, et al.. (2025). Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm. Leukemia. 39(4). 917–928.
2.
Li, Yaping, X. H. Niu, Ge Zhang, et al.. (2025). Anti-alcoholism drug disulfiram inhibits PANoptosis by blocking mitochondrial permeabilization in macrophages. Frontiers in Immunology. 16. 1726408–1726408.
3.
4.
Jain, Akriti, Somedeb Ball, Onyee Chan, et al.. (2024). Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML. Annals of Hematology. 103(6). 1941–1945. 5 indexed citations
5.
Xie, Zhuoer, Ling Zhang, Peter Papenhausen, et al.. (2024). Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm. SHILAP Revista de lepidopterología. 2(2). 100062–100062.
6.
Komrokji, Rami S., Najla H. Al Ali, Zhuoer Xie, et al.. (2024). IDH-1 Somatic Mutations Are More Commonly Observed Among Patients with Concomitant Myelodysplastic Syndromes (MDS) and Autoimmune Rheumatoid Diseases (AIRD). Blood. 144(Supplement 1). 3228–3228.
7.
Zahra, Fatima Tuz, Onyee Chan, Jeffrey E. Lancet, et al.. (2024). Real World Outcomes of Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia: A Single Center Experience. Blood. 144(Supplement 1). 2415–2415. 1 indexed citations
8.
Atallah, Ehab, Michael S. Broder, Onyee Chan, et al.. (2024). U.S. Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML). Blood. 144(Supplement 1). 5052–5052.
9.
Jain, Akriti, Chen Wang, Somedeb Ball, et al.. (2024). Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia. Annals of Hematology. 104(1). 307–315. 2 indexed citations
10.
Ionescu, Filip, David A. Sallman, Kendra Sweet, et al.. (2024). Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell Transplant. Clinical Lymphoma Myeloma & Leukemia. 24(6). 400–406. 2 indexed citations
11.
Komrokji, Rami S., Luis E. Aguirre, Najla H. Al Ali, et al.. (2023). Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes. Blood Advances. 7(14). 3677–3679. 7 indexed citations
12.
13.
Komrokji, Rami S., Najla Al Ali, Onyee Chan, et al.. (2021). Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. Leukemia & lymphoma. 63(1). 199–204. 2 indexed citations
14.
Renneville, Aline, Mrinal M. Patnaik, Onyee Chan, Eric Padron, & Éric Solary. (2021). Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia. Leukemia. 35(10). 2739–2751. 7 indexed citations
15.
Sallman, David A., Onyee Chan, Nicole D. Vincelette, et al.. (2021). MYC overexpression is associated with an early disease progression from MDS to AML. Leukemia Research. 111. 106733–106733. 10 indexed citations
16.
Talati, Chetasi, Aaron D. Goldberg, Amanda Przespolewski, et al.. (2020). Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy. Leukemia Research. 93. 106367–106367. 13 indexed citations
17.
Ali, Najla Al, Onyee Chan, David A. Sallman, et al.. (2020). Fluorescence in Situ Hybridization (FISH) Utility for Risk Score Assessment in Patients With MDS With Normal Metaphase Karyotype. Clinical Lymphoma Myeloma & Leukemia. 21(1). e52–e56. 1 indexed citations
18.
Chan, Onyee, et al.. (2019). Cancer, Acute Lymphocytic Leukemia (ALL). StatPearls. 4 indexed citations
19.
Chan, Onyee & Eric Padron. (2019). Moving towards a uniform risk stratification system in CMML - How far are we?. Best Practice & Research Clinical Haematology. 33(2). 101131–101131. 2 indexed citations
20.
Cypess, Aaron M., Yih‐Chieh Chen, Ke Wang, et al.. (2012). Cold but not sympathomimetics activates human brown adipose tissue in vivo. Proceedings of the National Academy of Sciences. 109(25). 10001–10005. 264 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gualtiero Mariani Breakdown of academic impact, for papers by Jon Smythe Breakdown of academic impact, for papers by Elena Ossipova Breakdown of academic impact, for papers by Susan K. Brusnahan Breakdown of academic impact, for papers by Arnon Nagler Breakdown of academic impact, for papers by Sharon H. Choi Breakdown of academic impact, for papers by Natalie Wolkow Breakdown of academic impact, for papers by J Živný Breakdown of academic impact, for papers by Shohei Yokota Breakdown of academic impact, for papers by Hong‐Wei Gao
Rankless by CCL
2026